Novo Nordisk A/S (NYSE:NVO) CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company’s blockbuster drugs, Ozempic and Wegovy, stating that these medications are reducing the economic burden of obesity-related health issues.
In an interview with NBC Nightly News, Jørgensen emphasized the costly impact of obesity in the U.S., which exceeds $400 billion annually, asserting that the company’s treatments are helping alleviate this financial burden.
He dismissed accusations that Novo Nordisk operates as a drug cartel as “unfounded.”
Also Read: Novo Nordisk’s Ozempic Might Be Among 2027 Medicare Price Negotiation Targets.
Jørgensen’s comments come ahead of his scheduled testimony before a Senate committee next month, where he will address the pricing of Novo Nordisk’s widely popular diabetes and weight loss drugs.
Senator Bernie Sanders, chair of the Health, ...